Patent details

EP3023788 Title: COMPOSITIONS OF TUMOR SPECIFIC NEOANTIGENS FOR USE IN TREATING TUMOURS

  • Data
  • Documents

Basic Information

Publication number:
EP3023788
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP151982840
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
COMPOSITIONS OF TUMOR SPECIFIC NEOANTIGENS FOR USE IN TREATING TUMOURS
French Title of Invention:
COMPOSITIONS DE NÉOANTIGÈNES SPÉCIFIQUES DE TUMEUR UTILISÉ DANS LE TRAITMENT DES TUMEURS
German Title of Invention:
ZUSAMMENSETZUNGEN TUMORSPEZIFISCHER NEOANTIGENE ZUR VERWENDUNG IN DER BEHANDLUNG VON TUMOREN
SPC Number:

Dates

Filing date:
16/05/2011
Grant date:
12/02/2020
EP Publication Date:
25/05/2016
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
12/02/2020
EP B1 Publication Date:
12/02/2020
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
16/05/2020
Expiration date:
16/05/2031
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
05/02/2020
 
 

Name:
Dana-Farber Cancer Institute, Inc.
Address:
450 Brookline Avenue, Boston, MA 02215, United States (US)

Name:
The General Hospital Corporation
Address:
55 Fruit Street, Boston, MA 02114, United States (US)

Inventor

1

Name:
WU, Catherine
Address:
United States (US)

2

Name:
HACOHEN, Nir
Address:
United States (US)

Priority

Priority Number:
334866 P
Priority Date:
14/05/2010
Priority Country:
United States (US)

Classification

IPC classification:
A61K 39/00; A61P 35/00; G01N 33/68;

Publication

European Patent Bulletin

Issue number:
202007
Publication date:
12/02/2020
Description:
Grant (B1)
Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer: